Qvest to Accelerate Generative AI for Media and Entertainment Businesses in Collaboration with NVIDIA
10.9.2024 16:03:00 EEST | Business Wire | Press release
IBC2024 -- Qvest, a leading consultant and systems integrator in media-focused services, today announced a collaboration with NVIDIA to drive AI adoption in the media and entertainment industry. These solutions powered by generative AI (GenAI), will create new opportunities for revenue generation, customer engagement, and operational efficiency.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240910864873/en/
Christophe Ponsart - EVP and Applied AI Practice Co-Lead, Qvest US. (Photo: Business Wire)
Qvest is expanding its alliance program in artificial intelligence to further position the company as a leader in AI for media businesses. By fostering collaboration across industries and leveraging shared expertise, Qvest delivers tangible GenAI applications that drive ROI.
The collaboration with NVIDIA combines Qvest’s deep expertise in media and entertainment with NVIDIA’s leading AI capabilities and technology platform. This will deliver advanced AI-driven solutions that empower companies to harness the full potential of GenAI.
Using NVIDIA's AI technologies, Qvest is further developing GenAI offerings in its Applied AI practice that address the key business challenges of media companies and help increase their productivity, promote creativity and optimize processes.
“The collaboration with NVIDIA enables us to quickly deliver powerful use cases for media and entertainment companies. Together, we are helping our customers generate value from AI in areas most impactful for their business,” said Christophe Ponsart, EVP and Applied AI Practice Co-Lead, Qvest US.
A GenAI solution will be unveiled at the IBC Show in Amsterdam, streamlining content management and creation within existing media workflows for:
- Automated Metadata Tagging: Drastically reduces time and costs associated with manual cataloging by automating structured metadata tagging across multiple modalities (text, audio, vision).
- Accelerated Content Discovery: User enablement to quickly find relevant content across and within video assets.
- Empowered Content Generation: Generation and iteration on contextually relevant headlines, scripts, and narratives in seconds to accelerate time to market.
“Media and entertainment companies are looking to accelerate AI adoption to deliver enhanced experiences. By combining NVIDIA’s AI platform with Qvest’s industry expertise, Qvest is empowering customers to quickly move from idea to scalable implementation using the latest developments in AI,” said Richard Kerris, Vice President of Media and Entertainment at NVIDIA.
NVIDIA NIM inference microservices play a critical role in this collaboration, offering seamless hosting of state-of-the-art GenAI models for computer vision, content generation, audio transcription, and more. Companies can choose where to run their models, whether in the cloud or hosted locally, helping ensure that data remains secure while optimizing performance.
Qvest is committed to continuing its collaboration with NVIDIA, with plans to integrate NVIDIAHoloscan for Media, an AI-enabled, software-defined platform for live media, for real-time streaming ingestion and content discovery. This integration will help further enhance the capabilities of GenAI infrastructure, increasing security, reducing costs, boosting performance, and minimizing operational overhead.
Qvest’s GenAI accelerators, developed in collaboration with NVIDIA, will be showcased at IBC 2024, where attendees can experience a full range of tangible and practical GenAI use cases firsthand at Qvest’s booth (#10.C24). More about Qvest at IBC2024 at www.qvest.com/ibc2024
About Qvest
Qvest is a global leader in media-focused practices and services. Qvest supports companies holistically in their Digital Transformation with innovation, consulting and technology implementation services to achieve future-oriented change. With deep expertise in media, information and communications technology, Qvest supports its customers in transforming their business towards digitalization, cloud and AI. Qvest's customers include numerous global brands from industries such as media & entertainment, telecommunications, automotive, health & pharmaceuticals, consumer goods, retail, transportation, and logistics, as well as organizations from the public sector. In addition to its headquarters in Germany, the company operates locations across Europe, the USA, the Middle East, Southeast Asia, and Australia.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240910864873/en/
Contacts
Qvest Group GmbH
Christian Felder
Tel.: +49 174 9481 983
E-Mail: christian.felder@qvest.com
Web: www.qvest.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.qvest.com&e
sheet=54119793&newsitemid=20240910864873&lan=en-US&anchor=www.qvest.com&index=3&
md5=c0a5bdcc8dfc89ea26ad0ef9f0362b7d
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 23:30:00 EET | Press release
Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to
Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 23:30:00 EET | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that
Multi-Color Corporation Receives Court Approval of First Day Motions4.2.2026 22:30:00 EET | Press release
Multi-Color Corporation (“MCC” or the “Company”), a global leader in prime label solutions, today announced that it has received approval from the U.S. Bankruptcy Court for the District of New Jersey (the “Court”) for first day relief related to its prepackaged Chapter 11 filed on January 29, 2026. The approved relief affirms that the Company will operate in the normal course, pay all trade vendors and suppliers in full, and maintain a strong liquidity position during the restructuring. As part of this relief, the Court granted MCC immediate access to $125 million of $250 million in debtor-in-possession (“DIP”) new money financing, provided by certain holders of MCC’s secured first lien debt and its equity sponsor, CD&R. This funding will capitalize the business through the initial stages of the prepackaged Chapter 11 process. The Court also granted MCC authority to pay trade vendors and suppliers in full in the ordinary course, maintain wages and benefits without interruption, satisfy
InterSystems Honored with Four 2026 Best in KLAS Awards4.2.2026 19:00:00 EET | Press release
InterSystems, a creative data technology provider powering more than one billion health records globally, today announced it has received four Global 2026 Best in KLAS awards. The company earned a #1 ranking for Acute Care EHR in Asia, Oceania, and France, as well as for Shared Care Records in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260204241673/en/ InterSystems earns four Best in KLAS awards for 2026 Best in KLAS is KLAS Research’s annual recognition of top-performing healthcare technology and services solutions, based entirely on feedback from healthcare provider organizations. Awards are given within defined software and services market segments evaluated by KLAS Research using a standardized methodology that reflects customer experience and performance. In addition to U.S. market segments, KLAS also recognizes top-performing solutions through its Global (Non-U.S.) Best in KLAS Awards, which are based on fe
Onego Bio Strengthens Board with Appointment of Dr. Antti Vasara4.2.2026 17:00:00 EET | Press release
Onego Bio, the food ingredient company producing non-animal egg protein through precision fermentation, today announced that Dr. Antti Vasara has joined its board of directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260204881159/en/ Dr. Antti Vasara Dr. Vasara brings more than 25 years of global experience in science, technology, and commercial strategy. Most recently, he served as President and CEO of VTT Technical Research Centre of Finland, where he led one of Europe’s foremost deep tech research organizations. His distinguished career spans senior leadership roles in industry and innovation policy—including impactful work with Nokia and strategic contributions to European research and development initiatives. “Antti is one of the most respected leaders in science and innovation,” said Maija Itkonen, CEO of Onego Bio. “His deep understanding of technology commercialization and ecosystem level strategy will be inva
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom